Phase 3 Trial of Brepocitinib in Dermatomyositis

This source describes a phase 3 clinical trial evaluating the efficacy and safety of brepocitinib, an oral medication designed to treat adults with dermatomyositis. The study compared two different doses of the drug against a placebo over a one-year period, specifically focusing on patients whose condition had not responded well to previous therapies. Researchers found that the 30-mg dose significantly improved muscle strength, skin health, and overall physical function while allowing patients to reduce their reliance on steroids. Conversely, the 15-mg dose did not meet the necessary benchmarks for statistical significance compared to the placebo group. While the higher dose proved effective, it was also associated with an increased risk of serious infections compared to the other groups. Ultimately, the authors conclude that high-dose brepocitinib offers a promising new systemic treatment option for managing this complex autoimmune disease.